focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
It is really frustrating that new investors have to justify themselves on these BBs. I see it all the time. The motives of any new poster are immediately called into question. I'm just a PI just like you. Not that it is any of your business, but I have 78,234 shares I bought at 0.01268 on 8 April for a small investment of 992.09 - which was all I could afford at the time. I would have liked to have topped up on the recent dips but I couldn't. I shall go back into my hole and will continue to read rather than comment or ask questions.
I think I'm one of your bored traders @bigbench. I bought in 3 times in March so my average is not too bad but it's just so tedious waiting for news. Holding for now but very tempted to sell the tranche I'm positive in.
Can you explain to a newby investor (in at 1.268 on 8 April) why there would be an extended auction part way through the day please, or if this just notification that there will be an extended trading period after the bell?
Another (planted?) article in this weekend's Sunday papers. Why wasn't this deemed newsworthy at the time?
"Local council extends huge loan to billionaire Matt Moulding, founder and boss of beleaguered online retailer The Hut Group"
It's exciting to watch...!
Don't filter CWWX. I think he's genuine.
In the last 5 years, the FDA has been more open-minded with regards to smaller biotech companies, and has been more flexible in allowing them to get past the double-blind test – particularly for diseases with unmet need and “orphan designations”. In spite of this, valuations are incredibly low for these companies, as Covid-19 delayed crucial human trials. This sector is currently vastly underfunded, something that Vulpes hopes to change.
With a decade of experience investing in UK Biotech companies, and a team of expert scientific advisors, we has proven time and time again we can identify and manage what will ultimately become high-return investments.
Vulpes Life Sciences
The Vulpes Life Sciences Fund is a rare co-investment fund that invests in undervalued companies that possess superior cutting-edge technology. This encompasses cell and gene therapy, diagnostics, medical device technologies and regenerative medicine.
- We seek value investments in under-priced UK biotech companies with strong, under-appreciated medical breakthroughs.
- We use a hands on activist approach to realise shareholder value and drive the business forward.
- We use long term patient capital to invest in businesses where we have high conviction
https://vulpesinvest.com/vulpes-life-sciences/
I've not done any more digging than that
AGM is 12 May.
I'm not a big holder here but I think other companies have more potential.
My personal dilemma is whether to cash out before 12 May or hope for positive results.
https://simplywall.st/stocks/gb/materials/aim-atm/afritin-mining-shares
Trading at 96.5% below our estimate of its fair value
Earnings are forecast to grow 86.27% per year
305? I was in at the initial offering at over 750!!
Back in the day and a tiny investor. I bought into all the hype. It was in my ISA and I ignored it for years thinking it would accrue growth. You lot have made me feel v v old!!
Recently I've had the liquid finances to average down to 105.
I'll review my holding in 6 months.
But times have changed. People have bigger TVs at home now, are willing to wait to view a new release and £10 a ticket for a family of four is a big spend in these £ crunch times (might be different in the winter when it's cheaper to visit the cinema rather than put on the central heating at home).
Hoping I'm wrong. Will continue to hold for 6 months and review my investment again then.